Renal denervation for hypertension
Cardiovascular therapies and procedures
The Symplicity™ blood pressure procedure provides a
complementary approach to hypertension (HTN) treatment.
Il tuo browser è obsoleto
Con un browser aggiornato, l'esperienza sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.
Si, sono un operatore sanitario
Note: Ai sensi e per gli effetti dell’Art. 76 D.P.R. 445/2000 consapevole della responsabilità e delle conseguenze civili e penali previste in caso di dichiarazioni mendaci e/o formazione od uso di atti falsi, nonché in caso di esibizione atti contenenti dati non più corrispondenti a verità e consapevole altresì che qualora emerga la non veridicità del contenuto della presente decadranno i benefici per i quali la stessa è rilasciata confermo di essere un OPERATORE SANITARIO.
I contenuti presenti in questo sito contengono informazioni rivolte agli operatori sanitari, in quanto si riferiscono a prodotti rientranti nella categoria dei dispositivi medici che richiedono l’impiego o l’intervento da parte di professionisti del settore medico-sanitario.
Cardiovascular therapies and procedures
The Symplicity™ blood pressure procedure provides a
complementary approach to hypertension (HTN) treatment.
adults with hypertension worldwide1
of hypertension patients do not have their blood pressure under control1
of hypertension patients become non-adherent to their medication within one year2
Hypertension is a leading preventable cause of heart attack, stroke, and death.3 But medication and lifestyle modifications are not always enough to control it.
Symplicity Spyral Renal Denervation Procedure - (03:26)
Seen how the Symplicity Spyral renal denervation procedure works to help treat hypertension.
Maggiori informazioni
Less information (see less)
The Symplicity Spyral™ renal denervation system supplies precisely controlled and targeted radiofrequency (RF) energy to the renal nerves, safely disrupting the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.7
The Symplicity blood pressure procedure is proven to achieve safe and clinically meaningful blood pressure reduction in the presence and absence of medications in multiple clinical trials and a real-world patient registry.4-6,8
Professor Roland Schmieder, M.D., presents key findings on cardiovascular risk reduction after the Symplicity blood pressure procedure.
Prof. Roland Schmieder - (05:47)
A photo of Prof. Roland Schmieder, a leading expert in renal denervation (RDN), presenting data about cardiovascular risk reduction after RDN.
Maggiori informazioni
Less information (see less)
Gain access to resources to introduce the Symplicity blood pressure procedure to your community successfully.
See how the Symplicity blood pressure procedure can enhance your hypertension treatment strategies as a complementary approach.
Explore CME courses, peer presentations, training materials, and other educational content about the Symplicity procedure.
In typical uncontrolled hypertension patients.
ANCOVA adjusted; secondary efficacy analysis.
RDN arm reduction from baseline.
Compared to modeled control group in the GLOBAL SYMPLICITY REGISTRY.
World Health Organization. Hypertension fact sheet. https://www.who.int/news-room/fact sheets/detail/hypertension. Published August 25, 2021. Accessed November 3, 2021.
Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Hypertension. 2013;31(4):766-774
Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. JAMA Cardiology. 2017:1;2(7):775–781.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet. 2020;395:1444–1451
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022; 399:1401-1410.
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2020;395:1444–1451.
Coates P, Tunev S, Trudel J, et al. Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation. Cardiovascular Revascularization Medicine. 2022.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
Schmieder R, Böhm M, Schlaich M, et al. Modeled Clinical Event Reductions at Three Years in High-Risk Hypertension Patients Treated with Renal Denervation. Presented at Deutsche Gesellschaft fur Kardiologie 2021.
Medtronic Italia S.p.A. Società a socio unico soggetta ad attività di direzione e coordinamento da parte di Medtronic PLC.
Cap. soc. € 1.200.487,00 - Codice fiscale, partita IVA e numero di iscrizione al Registro delle Imprese di Milano-Monza-Brianza-Lodi 09238800156 – REA MI – 1275682. Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano.